Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance
Triplet combinations containing a proteasome inhibitor are a standard of care in newly diagnosed multiple myeloma (NDMM). We examined the long-term efficacy and safety of the all-oral combination of weekly ixazomib plus lenalidomide-dexamethasone (IRd), followed by single-agent ixazomib maintenance...
保存先:
| 主要な著者: | , , , , , , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | 英語 |
| 出版事項: |
2019
|
| オンライン･アクセス: | https://doi.org/10.1038/s41375-019-0384-1 https://www.nature.com/articles/s41375-019-0384-1.pdf |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|